Working… Menu

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure (DEFEAT-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01112579
Recruitment Status : Completed
First Posted : April 28, 2010
Results First Posted : October 29, 2015
Last Update Posted : October 29, 2015
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm and Heart Failure

Brief Summary:
The purpose of this study is to determine the feasibility of spinal cord stimulation (SCS) as a chronic therapy for systolic heart failure.

Condition or disease Intervention/treatment Phase
Heart Failure Device: Medtronic PrimeADVANCED Neurostimulator Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure
Study Start Date : April 2010
Actual Primary Completion Date : January 2014
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Treatment Device: Medtronic PrimeADVANCED Neurostimulator
Heart failure therapy

Control Device: Medtronic PrimeADVANCED Neurostimulator
Medical management
Other Name: Medical management

Primary Outcome Measures :
  1. Evaluate the Reduction in Left-ventricular End Systolic Volume Index (LVESVi) After 6 Months of Spinal Cord Stimulation (SCS) Therapy in the Treatment Arm Compared to the Control Arm. [ Time Frame: Baseline and 6 months ]

Secondary Outcome Measures :
  1. Characterize the Change in proBNP Between the Treatment Arm and Control Arm Through 6 Months [ Time Frame: Baseline and 6 Months ]
  2. Characterize the Change in Peak Oxygen Uptake Between the Treatment Arm and Control Arm Through 6 Months [ Time Frame: Baseline and 6 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Left Ventricular Ejection Fraction (LVEF) of 35 percent or less
  • New York Heart Association (NYHA) functional Class III at time of screening
  • QRS duration less than 120 milliseconds (ms)
  • Left Ventricular End Diastolic Diameter (LVEDD) of 55 millimeters (mm) to 80 mm as determined by echocardiography within the past 6 months
  • Receiving stable optimal medical therapy for heart failure prior to enrollment
  • Serum creatinine less than or equal to 3.0 milligrams per deciliter (mg/dL)
  • 18 years of age or older
  • Willing and able to comply with study procedures
  • Expected lifespan greater than 12 months beyond study enrollment as assessed by physician

Exclusion Criteria:

  • Interruption of thromboprophylaxis (e.g., heparin, LMWH, warfarin, aspirin, dabigatran, clopidogrel) would pose an unacceptable health risk (e.g., patient with an abnormal bleeding time), as determined by physician
  • Polyneuropathy
  • Requires diathermy including shortwave diathermy, microwave diathermy, or therapeutic ultrasound diathermy
  • Unable to perform an exercise capacity test
  • Pregnant or planning to become pregnant during this study
  • Currently enrolled or plans to enroll in another investigational device or drug study that may confound the results of this study
  • Had Coronary Artery Bypass Graft/Percutaneous Coronary Intervention/Bare Metal Stent (CABG/PCI/BMS) procedures within the past 90 days
  • Had a heart transplant
  • Has complete heart block
  • Had Acute Coronary Syndrome within the past 90 days
  • Has congenital heart disease with significant hemodynamic shunting
  • Has chemotherapy-induced heart failure
  • Has reversible cardiomyopathy
  • Has severe mitral regurgitation (greater than 60 percent regurgitant fraction or greater than 0.3 centimeters squared (cm2) regurgitant orifice area)
  • Has diagnosed unstable angina pectoris
  • Has unstable coronary artery disease
  • Has a Cardiac Resynchronization Therapy (CRT) device implanted and is receiving CRT therapy
  • Has a non-Medtronic Implantable Cardioverter Defibrillator (ICD), pacemaker, or any non-transvenous defibrillation lead
  • Has a Medtronic ICD whose sensing threshold cannot be programmed to 0.3mV or greater
  • Has an existing neurostimulator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01112579

Layout table for location information
United States, Florida
Miami, Florida, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Pennsylvania
Allentown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, Vermont
Burlington, Vermont, United States
United States, Washington
Spokane, Washington, United States
Canada, British Columbia
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Czech Republic
Prague, Czech Republic
Berlin, Germany
Herne, Germany
Rome, Italy
Groningen, Netherlands
Maastricht, Netherlands
Zwolle, Netherlands
South Africa
Cape Town, South Africa
Johannesburg, South Africa
Gothenburg, Sweden
Stockholm, Sweden
Sponsors and Collaborators
Medtronic Cardiac Rhythm and Heart Failure
Layout table for investigator information
Principal Investigator: Douglas P Zipes, M.D. Krannert Institute of Cardiology
Principal Investigator: Heinz Theres, M.D. Charite Universitatsmedizin Berlin - Campus Charite Mitte
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medtronic Cardiac Rhythm and Heart Failure Identifier: NCT01112579    
Other Study ID Numbers: DEFEAT-HF
First Posted: April 28, 2010    Key Record Dates
Results First Posted: October 29, 2015
Last Update Posted: October 29, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases